Teneligliptin Hydrobromide/Canagliflozin Combination Tablets (Canalia) is a dual-mechanism antidiabetic fixed-dose combination preparation developed by Mitsubishi Tanabe Pharma (Japan) and co-promoted in collaboration with Daiichi Sankyo. As the first fixed-dose combination of a DPP-4 inhibitor and an SGLT2 inhibitor approved in Japan in 2017, it demonstrates significant clinical value in the treatment of type 2 diabetes.

Indications for Teneligliptin Hydrobromide/Canagliflozin Combination Tablets (Canalia)

Target Population and Eligibility Criteria

Teneligliptin Hydrobromide/Canagliflozin Combination Tablets are explicitly indicated for adult patients with confirmed type 2 diabetes who meet the following condition: inadequate blood glucose control despite sufficient dietary management and exercise therapy.

This medication is not indicated for type 1 diabetes, diabetic ketoacidosis, hyperosmolar hyperglycemic state, or other conditions requiring emergency insulin treatment.

Principles of Use

In principle, the switch to this combination preparation should be considered only when patients have been stably using a combination of teneligliptin hydrobromide (20 mg daily) and canagliflozin (100 mg daily), or when the therapeutic effect of either single agent alone is insufficient.

This medication should not be used as the first-line treatment for type 2 diabetes, reflecting the concept of stepped therapy.

Dosage Form, Strength, and Characteristics of Teneligliptin Hydrobromide/Canagliflozin Combination Tablets (Canalia)

Dosage Form and Strength

Dosage form: Film-coated tablets.

Strength: Each tablet contains 20 mg of teneligliptin hydrobromide and 100 mg of canagliflozin.

Physical Characteristics

Appearance: Light orange film-coated tablets.

Dimensions: 8.6 mm in diameter and 4.5 mm in thickness.

Weight: 244 mg per tablet.

Composition

Active ingredients: Teneligliptin Hydrobromide Hydrate and Canagliflozin Hydrate.

Synergistic dual mechanism: The combination preparation exerts its effect through a dual mechanism—DPP-4 inhibitor increases the level of active incretins, while SGLT2 inhibitor reduces renal glucose reabsorption.

Storage Instructions for Teneligliptin Hydrobromide/Canagliflozin Combination Tablets (Canalia)

Storage Conditions

Storage method: Store at room temperature.

Specific requirements: No special temperature control is required; protect from direct sunlight and humid environments.

Expiration Date Management

Shelf life: 36 months.

Precautions: Store in the original packaging and ensure the container is tightly sealed.

Usage Recommendations

To maintain drug stability, it is recommended to store the medication in a dry place out of the reach of children. Close the bottle cap immediately after taking the medication.

Transferring the medication to other containers is not recommended, as this may affect its efficacy.